Skip to main content

United States News All stories

Every story in this section, newest first — page 144 of 373.

Grafa

Merck gains EU approval for Keytruda plus Padcev in bladder cancer

Merck (NYSE:MRK) announced that the European Commission approved KEYTRUDA (pembrolizumab), in combination with Padcev (enfortumab vedotin-ejfv), as neoadjuvant treatment followed by adjuvant treatment after radical cystectomy for adults with resectable muscle-invasive bladder cancer who are ineligible for cisplatin-containing chemotherapy.

Read more: Merck gains EU approval for Keytruda plus Padcev in bladder cancer